SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 12, 2017
SERES THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
200 Sidney Street
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants Telephone Number, Including Area Code: (617) 945-9626
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01.||Regulation FD Disclosure.|
On June 12, 2017, Seres Therapeutics, Inc. (the Company, we, and our) posted an updated corporate slide presentation, including reaffirmed financial guidance and information regarding the Companys clinical trials, on its website at www.serestherapeutics.com. Updated clinical trial disclosures include (i) the initiation of the SER-109 ECORSPOR III study; (ii) the designation of the SER-109 ECOSPOR III study as a Phase 3 trial; and (iii) the planned expansion of the SER-262 Phase 1b study and the resulting modification in the timing of expected study results to early 2018. A copy of the slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
|Item 9.01.||Financial Statements and Exhibits.|
|99.1||Seres Therapeutics, Inc. Corporate Slide Presentation as of June 12, 2017|
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this report that do not relate to matters of historical fact should be considered forward-looking statements, including the planned expansion for the SER-262 Phase 1b study and the timing of study results for the SER-262 Phase 1b study.
These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding, which may not be available; our limited operating history; the unpredictable nature of our early stage development efforts for marketable drugs; the unproven approach to therapeutic intervention of our microbiome therapeutics; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; potential delays in enrollment of patients which could affect the receipt of necessary regulatory approvals; potential delays in regulatory approval, which would impact the ability to commercialize our product candidates and affect our ability to generate revenue; any fast track or Breakthrough Therapy designation may not lead to faster development, regulatory approval or marketing approval; our possible inability to receive orphan drug designation should we choose to seek it; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; our lack of experience in manufacturing our product candidates; the potential failure of our product candidates to be accepted on the market by the medical community; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; potential competition from biosimilars; failure to obtain marketing approval internationally; post-marketing restrictions or withdrawal from the market; anti-kickback, fraud, abuse, and other healthcare laws and regulations exposing us to potential criminal sanctions; recently enacted or future legislation; compliance with environmental, health, and safety laws and regulations; protection of our proprietary technology; protection of the confidentiality of our trade secrets; changes in United States patent law; potential lawsuits for infringement of third-party intellectual property; our patents being found invalid or unenforceable; compliance with patent regulations; claims challenging the inventorship or ownership of our patents and other intellectual property; claims asserting that we or our employees misappropriated a third-partys intellectual property or otherwise claiming ownership of what we regard as our intellectual property; adequate protection of our trademarks; ability to attract and retain key executives; managing our growth could result in difficulties; risks associated with international operations; potential system failures; the price of our common stock may fluctuate substantially; our executive officers, directors, and principal stockholders have the ability to control all matters submitted to the stockholders; a significant portion of our total outstanding shares are eligible to be sold into the market; unfavorable or lacking analyst research or reports; and we are currently subject to securities class action litigation. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 7, 2017 and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this report. Any such forward-looking statements represent managements estimates as of the date of this report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this report.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|SERES THERAPEUTICS, INC.|
|Date: June 12, 2017||By:|
|Name: Thomas J. DesRosier|
|Title: Executive Vice President and Chief Legal Officer|
|99.1||Seres Therapeutics, Inc. Corporate Slide Presentation as of June 12, 2017|
Corporate Presentation June 2017 Exhibit 99.1
Forward looking statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and uncertainties (such as those detailed in the Company’s periodic filings with the SEC) that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Any forward looking statements included herein represent our views as of today only. We may update these statements, but we disclaim any obligation to do so.
Seres Investor highlights Expansive therapeutic opportunity utilizing the microbiome, a highly promising new area of medicine Seres is a leader in microbiome drug development with differentiated capabilities Broad pipeline in infectious, inflammatory and immune, metabolic and liver diseases Experienced, accomplished leadership team Strong cash and strategic position Platform Opportunity Pipeline Team Runway
The microbiome is essential to human health Infectious Disease A diverse microbiome resists colonization by exogenous pathogens Exposure to broad spectrum antibiotics, and resulting gut microbiome dysbiosis, increase risk for C. difficile infection and colonization / infection by multi-drug resistant organisms Inflammation and Immunology Microbiome known to alter regulatory T cells and Th17 T cell activation Role in inflammatory bowel disease (Ulcerative colitis and Crohn’s disease) as well as allergy, rheumatoid arthritis and multiple sclerosis The composition of the microbiome has been demonstrated to impact the efficacy and safety of immuno-oncology checkpoint inhibitors Metabolic Disease Effects on liver function, glucose utilization, and caloric availability Microbiome, and bacterial bile acid metabolism, implicated in several metabolic diseases (e.g. diabetes, obesity, liver diseases) Selected references: Infectious disease / C. difficile: Leffler and Lamont, NEJM, 2015; Ulcerative colitis: Paramsothy et al. Lancet, 2017; Moayyedi et al. Gastroenterology, 2015; Immuno-oncology: Vetizou M et al., Science 2015.; Slvan A. et al., Science 2015.; Dubin et al., Nature, 2016. NASH: Le Roy et al., Hepatology, 2012. Metabolic syndrome: Perry et al. Nature, 2016, Ridaura VK et al., Science 2013. Primary sclerosing cholangitis Tabibian JH et al., Hepatology, 2016
Prioritize serious diseases where dysbiosis of the gut microbiome has a causal role Focused clinical efforts Computational biology Basic microbiome research Microbiology Translational science Clinical development Advanced manufacturing World class, differentiated, microbiome expertise Collaborate with leading academic centers to advance research in promising therapeutic areas Research in new therapeutic areas Business strategy Inflammatory bowel disease C. difficile infection
Robust microbiome therapeutics pipeline SER-109 DISCOVERY EFFORTS PRECLINICAL PHASE 1 PHASE 2 SER-262 SER-287 Inflammatory bowel diseases Primary sclerosing cholangitis, NASH and other liver diseases Immuno-oncology and hematopoietic stem cell transplant SER-301 ACADEMIC COLLABORATOR SER-155 Recurrent C. difficile Primary C. difficile Ulcerative colitis Inflammatory Bowel Disease (IBD) Prevention of infection and GVHD following hematopoietic stem cell or solid organ transplant Synthetically fermented Infectious Inflammatory Based on interactions with the U.S. Food and Drug Administration , ECOSPOR III will be designated a Phase 3 trial and the company expects that this single pivotal study may support SER-109 registration and approval. Collaboration with Nestlé Health Science regarding C. difficile and IBD programs for markets only outside of North America Obesity/metabolic syndrome Biologically sourced Genetic metabolic diseases PHASE 3
Differentiated microbiome R&D platform Computational discovery using human clinical datasets to allow rational design of microbiome drugs in multiple therapeutic areas Vast microbial strain library and commensal bacteria culturing know-how Disease targeted metabolic, immunological, & efficacy screens for ‘r-group’ informed lead optimization Rationally Designed Ecologies Functional pathways Microbial networks In silico derivation of ‘backbone’ functional microbial ecologies Genomic & phenotypic characterization of microbial strains & compositions using high resolution whole metagenomic shotgun sequencing, resolving down to strain level >14,000 strains spanning broad biological breadth Compositional Variants Efficacy Metric Phylogenetically-informed ”R-group” Optimization Only company with clinical stage microbiome development programs, human microbiome datasets, and clinical datasets before and after treatment
CMC platform enables manufacture of cGMP-compliant, oral, microbiome therapeutic candidates Fermentation of anaerobic and spore-forming microbes Formulation, Filling, Delivery & Packaging enabling active product delivery cGMP Isolation of spores from complex biological materials Synthetic candidates Biologically sourced Novel QC assays for Safety, Identity, Strength, Purity, and Quality including microbiome characterization Absorb. Lumin. DPA Tb+3 Novel germination, cultivation, and sporulation strategies enabling increased culture diversity and productivity aa
Clostridium difficile Infection Overview and R&D Programs Leading the Microbiome Revolution
C. difficile infection overview Infectious disease caused by toxin producing anaerobic, spore-forming bacteria, resulting in diarrhea, abdominal pain, fever, and nausea Leading cause of hospital-acquired infection in the US; approximately 29,000 deaths/year Infection caused by two-hit process: Disruption of gut microbiome and exposure to pathogenic spores ~25% of patients with primary CDI recur Risk of relapse increases with each recurrence Leffler and Lamont, New England Journal of Medicine, 2015
Treatment landscape & disease burden Economic burden as high as $4.8B in U.S. acute-care facilities1 Recurrent CDI episode ~$18K2; >$50K for cycle of recurrences Modality Characteristics Antibiotics Perpetuates microbiome dysbiosis, creating C. difficile infection susceptibility High recurrence rates, especially in recurrent cases Fecal Transplant Invasive procedures (colonoscopy or NG-tube) Potential for transmission of human pathogens No FDA approved products Antibodies Limited efficacy in Phase 3 studies Does not address underlying microbiome dysbiosis Complex administration, not patient-friendly Vaccines Unproven efficacy until Phase 3 is complete Complex to identify and vaccinate elderly at-risk groups High Unmet Medical Need Dubberke and Olsen, Clinical Infectious Diseases 2012; 2. Ghantoji et al., Journal of Hospital Infection, 2010. High Treatment Costs
Dysbiosis and potential for therapeutic intervention Hypothetical patient course Healthy person with intact pathogen resistance High diversity microbiome Use of broad spectrum antibiotics Active C. diff. infection Antibiotic treatment of C. diff. infection Potential for microbiome therapy to reduce risk of C. diff. recurrence Antibiotic mediated C. diff. killing Antibiotic exacerbation of dysbiosis Gastrointestinal microbiome diversity C. diff. bacterial & cytotoxin levels C. diff. recurrence risk C. diff. outgrowth & cytotoxin production Potential for microbiome therapy to increase bacterial diversity in the GI tract Antibiotic mediated dysbiosis
SER-109 Phase 1b and Phase 2 (8-week) study results n=59 n=30 n=28 n=15 n=31 n=15 Phase 1b Open Label, Single-Arm (n=30; 4 sites) Phase 2 – Interim results Randomized, Placebo-Controlled (n=89; randomized 2:1; 28 sites) Primary Endpoint CDI recurrence up to 8 weeks defined by: >3 unformed stools over 1 day CDI recurrence up to 8 weeks defined by: ≥3 unformed stools/day for ≥2 days Efficacy 13% recurrence per protocol 3 of 4 patients with recurrent transient diarrhea, did not require antibiotic treatment and tested negative for C. diff. at 8 weeks SER-109: 44% (26 of 59) recurrence Placebo: 53% (16 of 30) recurrence Relative risk recurrence between arms not significant Safety Most AEs were mild to moderate and transient Most frequent AEs were gastrointestinal symptoms similar in nature to that seen in FMT trials or following CDI SER-109 is well-tolerated with an acceptable safety profile, it was associated with a small increase in gastrointestinal adverse effects, particularly diarrhea, compared to placebo (25% vs 14%) Phase 1b study results: Khanna et al. The Journal of Infectious Diseases; Phase 2 results: see July 31, 2016 press release (study results), and January 31, 2017 press release (Phase 2 study analyses)
SER-109 Phase 2 study post read-out analyses and findings SER-109 analyses Key issues addressed Clinical Detailed analyses of clinical data Investigation of C. difficile diagnostics Pharmacodynamics / microbiome analyses Investigation of drug activity Chemistry, Manufacturing and Controls (CMC) Drug product distribution and handling Phase 1b to Phase 2 manufacturing and formulation changes, and potential impact on drug activity Diagnosis - Misdiagnoses may have occurred both in some patients entering the trial, as well as for recurrences diagnosed during the study Key Findings: Factors contributing to SER-109 Phase 2 study result Dose - The dose used in the Phase 2 study may have been suboptimal in certain patients See January 31, 2017 press release for additional information
Phase 3 SER-109 ECOSPOR III study now underway Seres and FDA agreement on key design elements of a SER-109 Phase 3 Based on FDA feedback ECOSPOR III designated as a Phase 3 study The ECOSPOR III Phase 3 study is the first pivotal trial in the emerging field of oral microbiome therapeutics ECOSPOR III to utilize a SER-109 dose approximately 10-fold higher than the dose used in the prior Phase 2 study, administered over three days Multiply recurrent C. difficile patients, screened by toxin assay All subjects treated with standard of care antibiotics Primary endpoint: C. diff. recurrence, at up to 8 weeks Safety follow-up to 24 weeks Phase 3 ECOSPOR III (SERES-012) study design SER-109 (n = 160) Placebo (n =160)
SER-262: Synthetic Ecobiotic® therapeutic candidate for primary C. difficile infection SER-262 strains utilize multiple carbon sources In vitro fermentation Oral, microbiome therapeutic candidate comprising twelve strains of fermented, rationally selected bacterial spores Bacteria species selected based on analysis of SER-109 Phase 1b microbiome data, biological and phylogenetic heterogeneity, and preclinical efficacy in C. difficile infection mouse model Data support a mechanism of action in which SER-262 strains compete for C. difficile preferred carbon sources For additional information, see 2016 American Society of Microbiology conference poster, available on Seres website under ‘Our Science’
SER-262 Phase 1b dosing study in patients with primary C. difficile infection Primary Objective Safety and tolerability at 24 weeks Relative risk of C. difficile recurrence compared to placebo at up to 8 weeks Secondary Objectives Time to C. difficile recurrence Relative risk of recurrence at up to 4, 12, and 24 weeks after treatment Cohort A: Tx with 104 spores (n=10); placebo (n=2); single dose Cohort B: Tx with 105 spores (n=10); placebo (n=2); single dose Cohort C: Tx with 106 spores (n=10); placebo (n=2); single dose Cohort D: Tx with 107 spores (n=10); placebo (n=2); single dose 60+ patients with primary C. difficile infection Cohort E: Tx with 108 spores (n=10); placebo (n=2); single dose Multi Dose Cohorts: Tx spores (n=10); placebo (n=2); Dosing provided over three days
Inflammatory Bowel Disease Overview and R&D Programs Leading the Microbiome Revolution
Selected references: Paramsothy et al. Lancet, 2017; Moayyedi et al. Gastroenterology, 2015 Multiple FMT studies provide proof of concept for microbiome therapy in ulcerative colitis Subject A, Baseline Subject A, 8-wk post FMT
SER-287 Inflammatory Bowel Disease (IBD) opportunity Significant unmet need for improved therapies for IBD Large US population: ~700K ulcerative colitis, ~700K Crohn’s Over half of patients do not respond to biologic therapies Many therapies are immunosuppressive, limiting widespread use SER-287 target profile: Oral Alternative mechanistic approach, potential mono or combo therapy Not expected to be immunosuppressive SER-287 development opportunity: Initial development as induction therapy for ulcerative colitis Potential development as UC maintenance therapy, Crohn’s disease
SER-287 Phase 1b study in ulcerative colitis patients is fully enrolled Primary Objective Change in composition of intestinal microbiome at 8 weeks Safety and tolerability Secondary Objectives Clinical responses, including complete remission, and endoscopic improvement Change in serum and fecal biomarkers Complement of microbiome metabolic pathways from stool, urine and blood Immunological and pathologic changes in mucosal biopsies Arm A (n~15): Placebo pre-treatment / SER-287 once weekly dosing for 8 weeks Arm B (n~10): Placebo pre-treatment / Placebo once daily for 8 weeks Arm C (n~15): Vancomycin pre-treatment / SER-287 once daily dosing for 8 weeks Arm D (n~15): Vancomycin pre-treatment / SER-287 once weekly dosing for 8 weeks ~55 mild-moderate UC patients failing standard-of-care
SER-301: Synthetic Ecobiotic® therapeutic candidate for inflammatory bowel disease Follow-on therapeutic candidate to SER-287 in preclinical development for inflammatory bowel disease Oral, microbiome therapeutic candidate comprising fermented, rationally selected bacteria Selection of SER-301 bacterial composition to be based on: SER-287 study data (clinical and microbiome analysis) Existing collaborations evaluating analysis of FMT ulcerative colitis clinical study data Preclinical screening for microbial function, immunological assay, and animal models
Additional R&D Opportunities Leading the Microbiome Revolution
SER-155: Synthetic Ecobiotic® therapeutic candidate to improve transplantation outcomes 1 Khanna et al, Journal of Infectious Disease 2016 2 Jenq, et al, Biology of Blood and Marrow Transplantation 2015, 3 Taur, et al., Blood 2015. 36% 60% 67% Overall Survival HSCT Patient Microbiome Health Correlates with Overall Mortality Risk3 Time (Years) Ecobiotic® synthetically derived therapeutic candidate to improve outcomes in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplants Designed to reduce both infection risk, and Graft vs. Host Disease (GvHD)
Immuno-oncology microbiome therapeutic opportunity Therapeutic Objectives To improve efficacy: Modulate immune response, improve clinical response to therapeutic checkpoint inhibitors To improve safety: Reduce anti-CTLA4 induced colitis by providing microbial ecologies correlated with improved patient outcomes
Collaborations with leading institutes to advance R&D progress Target Indication Academic Collaboration Inflammatory Bowel Disease Immuno-oncology Therapeutics Hematopoietic Stem Cell Transplantation Primary Sclerosing Cholangitis, NASH and Other Liver Diseases Obesity and Metabolic Syndrome Rare genetic metabolic diseases (e.g., urea cycle disorders, hepatic encephalopathy) Collaboration announcements: Mayo Clinic, see June 6, 2016 press release; Memorial Sloan Kettering, University of Pennsylvania, see May 12, 2016 press releases; Medical University of Graz and Research Institute of St. Joseph’s Hamilton, see May 4, 2016 press release; Massachusetts General Hospital, see June 22, 2016 press release.
Broad IP portfolio and regulatory exclusivity Families of Applications Nationalized Pending PCT Pending Provisionals SERES PATENT PORTFOLIO 15 9 2 REGULATORY EXCLUSIVITY years for new biological composition 12 years for new drug 10 7 ISSUED US PATENTS + LICENSED IP* Demonstrates rationally designed ecologies of spores and microbes are patentable Composition of matter and method claims Claims related to SER-109/CDI & colitis lead candidates through 2033 4 * Includes additional rights to intellectual property including a worldwide exclusive license to Memorial Sloan Kettering Cancer Center patent applications related to the use of bacterial compositions for treating HSCT patients and related areas
Resources to operate through 2018 Strong financial position Balance Sheet As of Mar. 31, 2017 Cash, cash equivalents and investments $202 M Income Statement Latest Quarter, as of Mar. 31, 2017 R&D ($20 M) G&A ($9 M) Net loss ($25 M) Common shares outstanding 40.4 M, as of Mar. 31, 2017 SER-109 Phase 3 study initiation triggers a $20 million milestone payment from Nestlé Health Science
SER-287: Ulcerative Colitis - Phase 1b read-out (H2 2017) SER-262: Primary C. difficile infection - Phase 1b read-out (by early 2018) Advancing new pipeline programs in infectious diseases, inflammatory and immune diseases (including immuno-oncology), metabolic and liver diseases Upcoming value-driving milestones